World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0026481124
Reproduction Date:

Title: Vabicaserin  
Author: World Heritage Encyclopedia
Language: English
Subject: 5-HT2c receptor agonist, Lorcaserin, 5-HT2C receptor, RS-56812, MPPF
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
Clinical data
Legal status
  • Uncontrolled
Routes Oral
CAS number  YesY
ATC code None
Chemical data
Formula C15H21ClN2 
Mol. mass 264.79 g/mol

Vabicaserin (SCA-136) was a novel antipsychotic and anorectic under development by Wyeth.[1] As of 2010 it is no longer in clinical trials for the treatment of psychosis.[1][2] It was also under investigation as an antidepressant but this indication appears to have been dropped as well.[3]

Vabicaserin acts as a selective 5-HT2C receptor full agonist (Ki = 3 nM; EC50 = 8 nM; IA = 100% (relative to 5-HT)) and 5-HT2B receptor antagonist (IC50 = 29 nM).[4][5][6] It is also a very weak antagonist at the 5-HT2A receptor (IC50 = 1,650 nM), though this action is not clinically significant.[4] By activating 5-HT2C receptors, vabicaserin inhibits dopamine release in the mesolimbic pathway, likely underlying its efficacy in alleviating positive symptoms of schizophrenia, and increases acetylcholine and glutamate levels in the prefrontal cortex, suggesting benefits against cognitive symptoms as well.[6][7][8]

See also


  1. ^ a b "Search of: vabicaserin - List Results -". 
  2. ^ "Enzyme Inhibition in Drug Discovery ... - Google Books". 
  3. ^ Prof John Kelly (2010). Principles of CNS Drug Development: From Test Tube to Patient. New York: Wiley.  
  4. ^ a b Rosenzweig-Lipson S, Dunlop J, Marquis KL (November 2007). "5-HT2C receptor agonists as an innovative approach for psychiatric disorders". Drug News & Perspectives 20 (9): 565–71.  
  5. ^ Tong Z, Chandrasekaran A, Demaio W, et al. (December 2009). "SPECIES DIFFERENCES IN THE FORMATION OF VABICASERIN CARBAMOYL GLUCURONIDE". Drug Metabolism and Disposition: the Biological Fate of Chemicals 38 (4): 581–590.  
  6. ^ a b "ECNP-2007 CIS". 
  7. ^ Stahl's essential psychopharmacology: neuroscientific basis and practical applications. Cambridge, UK: Cambridge University Press. 2008.  
  8. ^ Albert, JS (2012). Wood, MW, ed. Targets and Emerging Therapies for Schizophrenia. Hoboken, New Jersey: John Wiley & Sons, Inc.  

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.